DaVita Inc. (NYSE: DVA) - Deep Dive Research Report

Healthcare / Dialysis Services | Report date: 2026-06-08

Concalls used (most recent five): Q1 2026 (May 5, 2026), Q4/FY 2025 (Feb 2, 2026), Q3 2025 (Oct 29, 2025), Q2 2025 (Aug 5, 2025), Q1 2025 (May 12, 2025). The most recent call is 34 days old, well inside the 90-day requirement.

1. What the Company Does

DaVita keeps people with failed kidneys alive. When a person's kidneys stop working (a condition called end-stage renal disease, or ESRD, also called end-stage kidney disease, or ESKD), their blood is no longer filtered of waste and excess fluid. Without intervention they die within days to weeks. The fix is dialysis: a machine does the filtering the kidneys can no longer do. A typical patient comes in three times a week, sits in a chair for roughly four hours while their blood is pumped through a filter (a dialyzer) and returned cleaned, and does this for the rest of their life unless they receive a kidney transplant. DaVita runs the buildings where this happens. As of early 2026 it operates roughly 2,650 outpatient dialysis centers in the United States plus about 509 centers across 13 other countries, caring for around 282,000 patients globally.

The business is unusually stable for a healthcare company because the underlying demand is non-discretionary and recurring. A dialysis patient cannot defer treatment to next quarter, cannot shop on price in the moment, and remains a patient for years. The flip side is that the payer mix is dominated by the U.S. government. The vast majority of ESRD patients are covered by Medicare (federal law makes nearly everyone with ESRD Medicare-eligible regardless of age), which pays a fixed, regulated rate per treatment. A small slice of patients - those still on commercial/employer insurance, typically in the first 30 months after diagnosis before Medicare becomes primary - pay multiples of the Medicare rate. That thin commercial slice, roughly 10-11% of treatments, generates a hugely disproportionate share of profit. The entire economic model of DaVita rests on a large base of barely-profitable government-paid treatments cross-subsidized by a small base of highly-profitable commercial treatments.

DaVita was originally part of a company called Total Renal Care, a struggling, near-bankrupt dialysis operator. In 1999 Kent Thiry took over as CEO, rebuilt the operations and culture, and renamed the company DaVita ("he/she gives life" in colloquial Italian) in 2000. Thiry's tenure was defined by relentless consolidation - buying up independent and regional dialysis centers - and a distinctive, almost theatrical internal culture (the company calls itself "the Village," teammates are "citizens," and Thiry led mascot-costumed company meetings). The current CEO, Javier Rodriguez, took over in 2019 and has shifted emphasis toward two things: returning enormous amounts of cash to shareholders via buybacks, and building care models that get paid for keeping kidney patients healthy rather than just for running dialysis treatments.

"Think about it in years and not just a couple of quarters." - Javier Rodriguez, CEO, on the timeline for clinical innovations to reduce patient mortality (Q2 2025 concall, Aug 5 2025).

That quote captures the essence of the business. DaVita's biggest growth lever is not opening new centers - the U.S. market is mature and tightly controlled. It is keeping its existing patients alive longer. In dialysis, lower mortality literally equals more treatments and more revenue, which puts the company in the rare position where its commercial interest and its patients' interest point the same direction.

2. Business Segments

DaVita reports primarily as a single dominant operating segment (U.S. dialysis and lab) with two smaller reportable groupings layered on top: Integrated Kidney Care (IKC) and Other/Ancillary, which includes the International business. Below, each is treated as its own sub-report because the economics differ sharply.

2.1 U.S. Dialysis (the core, ~88% of consolidated revenue)

This is the engine. It is the network of ~2,650 outpatient centers plus the lab services that support them. What it does is straightforward to describe and very hard to replicate at scale: deliver chronic in-center hemodialysis (the three-times-a-week chair treatment), home hemodialysis, and peritoneal dialysis (a home-based method using the lining of the abdomen as the filter), plus the clinical labs that run the constant blood work dialysis patients require.

The core capability is operational, not technological. DaVita does not make the dialysis machines (it buys them, largely from Fresenius and Baxter). What it knows how to do is run thousands of small clinical facilities profitably under a fixed government reimbursement rate. That means staffing each center with nurses and patient-care technicians at exactly the right ratio, scheduling patients tightly across multiple daily "shifts" of chairs, managing the supply chain for dialyzers and drugs, hitting the federal clinical quality metrics that govern Medicare bonus/penalty payments, and capturing the commercial-insurance revenue during the patient's pre-Medicare window. Decades of building this muscle, plus the sheer density of the center network, are the moat.

It exists as the standalone core because everything else is built around it. Revenue per treatment (RPT) and patient care cost per treatment (PCC) are the two metrics management lives and dies by. In FY2025 RPT was roughly $410 (up 4.7% for the year), and the gap between RPT and PCC is essentially the whole business. Competitively this segment faces exactly one peer of comparable scale: Fresenius. It wins on U.S. scale and operational consistency; it is exposed on payer mix (any erosion of the commercial slice hits profit hard) and on its near-total dependence on a government-set rate.

2.2 Integrated Kidney Care (IKC) - the value-based-care bet

IKC is DaVita's attempt to get paid for outcomes rather than treatments. Instead of billing per dialysis session, IKC signs risk-based and value-based contracts with health plans, Medicare Advantage insurers, and government programs (notably CMS's Comprehensive Kidney Care Contracting, or CKCC, program). Under these arrangements DaVita takes responsibility for the total cost of care of a population of kidney patients and shares in the savings if it keeps them healthier and out of the hospital - through health monitoring, care coordination, predictive analytics on its own patient data, and earlier intervention in chronic kidney disease (CKD) before patients even reach dialysis.

The core capability here is data and clinical coordination. DaVita has the largest longitudinal dataset of kidney patients in the country, and IKC monetizes it by predicting which patients are about to crash and intervening first. The economics are lumpy and contract-driven: revenue is recognized as shared-savings results are confirmed, which can shift between quarters and years. In 2025 IKC reached its first profitable full fiscal year (adjusted operating income of about $22 million), ahead of the originally guided 2026 timeline. Management reported that in the CKCC program DaVita generated the highest total aggregate savings of any participant and a 4.5% improvement in gross savings rate since the program began (Q1 2026 concall, May 5 2026).

It exists separately because it is a fundamentally different business - insurance-like risk-bearing, not facility operations - with different competitors (it competes against "several unproven entrants" making aggressive pricing moves, per Q1 2025) and different economics. Strategically, management frames IKC as both the clinical flagship and the option on a future where the U.S. payment system rewards keeping kidney patients out of dialysis. It is the growth bet, not the cash cow.

2.3 International - the organic + M&A growth lever

DaVita operates, manages, or administers roughly 509 centers in 13 countries outside the U.S., serving about 80,000 patients. The biggest recent move was Brazil. International delivered about $114 million in full-year adjusted operating income in 2025, and management describes its growth as "half M&A and half organic," with margins improving as fixed overhead is leveraged across a larger base (Q4 2025 concall, Feb 2 2026).

The core capability is exporting the U.S. operating playbook into markets with different reimbursement systems and consolidating fragmented local providers - the same consolidation strategy that built the U.S. business, run again abroad where the market is less mature. It exists separately because the regulatory and reimbursement environment differs country by country, and because it is the one part of the business with a long runway of unit (center) growth, which the U.S. lacks. Competitively it runs into Fresenius again (a German company with a deeper international footprint) plus local and regional operators. Strategically it is the cleanest organic growth story in the group.

2.4 Other / Ancillary

A small collection of adjacencies, increasingly oriented around keeping dialysis patients out of the hospital. The notable 2025 development was a roughly $200 million minority investment alongside Ares' Private Equity Funds (which took the majority stake) to acquire Elara Caring, a home-health provider. The thesis: dialysis patients are frequently hospitalized and miss treatments; a home-health arm with kidney-specific protocols can reduce both, which feeds back into IKC's shared-savings economics and the core segment's treatment volumes (Q4 2025 concall, Feb 2 2026).

Segment summary

3. Products and Business Detail

DaVita's "product" is a clinical service, but it has a real catalogue of treatment modalities, drugs, and operational assets.

Treatment modalities. The dominant product is in-center hemodialysis: the patient travels to a center three times weekly for a ~four-hour session in a dialysis chair. The two home modalities are home hemodialysis (the patient or a partner runs a machine - DaVita uses NxStage machines supplied by Fresenius - at home, often more frequently and gently) and peritoneal dialysis (PD), which uses a catheter and the patient's own peritoneal membrane to filter, performed at home, often overnight via a cycler. Home modalities are strategically important: they are typically lower-cost, generally preferred by regulators and patients, and the U.S. government has pushed payment incentives toward home dialysis and transplant. DaVita also supports the transplant pathway - clinically the best outcome for a patient and, counterintuitively, something DaVita actively facilitates because IKC's value-based contracts reward total-cost reduction.

Pharmaceuticals administered in the bundle. Dialysis treatment includes drugs, the most economically significant of which recently are phosphate binders. ESRD patients can't clear phosphate, so they take binders with food. Historically these were paid under Medicare Part D (pharmacy benefit); effective January 2025, CMS folded phosphate binders into the dialysis "bundle" under a transitional add-on payment (TDAPA), meaning DaVita now dispenses and is reimbursed for them as part of treatment. This created a meaningful new revenue and income stream in 2025 (management guided binder contribution to operating income at roughly $50 million for the year), with a tilt toward iron-based binders, but also introduced an adherence problem - some patients obtain binders through other channels, so dispensing volumes ran below expectation (Q2 2025 concall, Aug 5 2025). Other bundle drugs include anemia management agents (ESAs) and IV iron.

Labs. DaVita runs central clinical laboratories that process the constant blood work dialysis patients require (electrolytes, hemoglobin, mineral metabolism). This is both a clinical necessity and a margin contributor inside the core segment.

The "manufacturing" process - i.e., running a center. The constraint set is: physical chairs (capacity), licensed clinical staff, the federal Conditions for Coverage that govern how a center must operate, state Certificate of Need rules that in many states limit how many new centers can open, and the quality metrics (the ESRD Quality Incentive Program) that adjust Medicare payment by up to a few percent based on clinical outcomes. A new center requires a medical director (a nephrologist), build-out, certification, and a patient base - which in practice usually comes from the local nephrologists who refer patients. This is why consolidation (buying existing centers with existing patients and referral relationships) has historically been a faster growth path than de-novo building. DaVita illustrated the operational layer in 2026 with internal tools like ScheduleHub, an AI system that re-optimizes patient and staff schedules in real time as each center's census changes (Q1 2026 concall, May 5 2026).

Geographies and milestones. The U.S. is ~88% of revenue and the historical core, built through two decades of acquiring independent and regional operators. International spans 13 countries; the Brazil acquisition (closed 2024-2025) made DaVita the provider caring for the most dialysis patients in the world by patient count. The 2025 milestones worth flagging: phosphate binders entering the bundle (a structural revenue change), IKC turning profitable a year early, and the Elara Caring home-health investment.

4. Customers

The word "customer" in dialysis is split between who consumes the service (patients) and who pays for it (payers). Both matter, and they behave completely differently.

Patients. ESRD patients are the consumers. They choose a center largely on geography (you go three times a week, so proximity dominates), on the referral of their nephrologist, and on continuity (once established at a center with a care team that knows them, patients rarely switch). The "buying decision" is really the nephrologist's referral plus the patient's location. Sales cycles don't exist in the conventional sense; the pipeline is the flow of newly-diagnosed ESRD patients (called "incident" patients, or "admits") into the local catchment. This is why two of the most-watched operating variables on every call are admits (new patients arriving) and mortality (patients leaving). Census - the running patient count - is the product of those two flows.

Payers - the real economic customer. Roughly 90% of treatments are paid by government programs (Medicare and Medicare Advantage, plus Medicaid), at fixed regulated rates that for the base business are near or below cost. The profit comes from the ~10-11% of treatments still covered by commercial/employer insurance, which pays multiples of the Medicare rate. The decision-maker on the commercial side is the health plan and, increasingly, the employer; the criteria are network adequacy (a plan needs dialysis coverage for its members) and price negotiation. This concentration is the defining feature of DaVita's customer base: it is not exposed to any single corporate account, but it is enormously exposed to two policy levers - the Medicare base rate (set by CMS) and anything that shrinks the commercial mix (e.g., patients shifting to Medicare Advantage, or the expiration of enhanced ACA premium tax credits that currently keep some patients on commercial exchange plans).

Switching costs and stickiness. For the patient, switching centers means disrupting a life-sustaining routine, re-establishing with a new care team, and often traveling farther - so churn is low and is dominated by mortality and transplant rather than competitive defection. For payers, DaVita is effectively un-switchable in many local markets because in a duopoly there often isn't an alternative network of sufficient scale. This is exactly the dynamic the FTC and antitrust plaintiffs are scrutinizing (see Section 5 and 8).

Contract structure and revenue predictability. Core dialysis revenue is essentially recurring and annuity-like: a stable census times three treatments a week times a known rate. There is no spot business and no order book to worry about; the predictability risk is not demand volatility but rate and mix. IKC is the opposite - lumpy, contract-by-contract, with shared-savings revenue recognized when results are confirmed, which is why management repeatedly warns that IKC income can shift between quarters and years (Q3 2025 concall, Oct 29 2025).

5. Competitive Landscape

The U.S. dialysis market is one of the cleanest duopolies in American healthcare. DaVita and Fresenius Medical Care together control roughly 73-80% of U.S. dialysis treatments. DaVita holds approximately 37% of U.S. centers and Fresenius roughly 34-38%, with each at a similar share. The remaining quarter of the market is fragmented: about 30 small multi-center operators (~15% combined), 700-750 independent centers (~10%), and a tail of non-profit and government centers.

DaVita wins against the long tail of independents on cost (scale buying power on machines and drugs), on its ability to absorb fixed regulatory and quality-reporting overhead, and on the density of its network in any given metro. Against Fresenius, the two are near-mirror images, with one structural difference: Fresenius is vertically integrated - it manufactures the dialysis machines, dialyzers, and much of the consumables that both companies use, and it is far larger internationally. DaVita is a pure-play services operator that buys its hardware (partly from Fresenius itself, including NxStage home machines). DaVita has generally run its U.S. service operation with stronger margins and has been the more aggressive returner of capital; Fresenius carries the manufacturing business and a heavier international and product footprint.

In IKC, the competitive set is different and earlier-stage: value-based kidney-care startups and "unproven entrants" (DaVita's words) bidding aggressively for risk contracts, plus the insurers' own care-management efforts. DaVita's edge there is its dataset and its installed patient base.

The barriers to entry are high and partly regulatory: state Certificate of Need laws, the federal Conditions for Coverage, the need for a nephrologist medical director and local referral relationships, the quality-reporting infrastructure, and the simple fact that a new entrant has to build local density to be cost-competitive against two incumbents who already have it. The structural risk to the moat is not a new entrant - it is the regulator. The FTC is investigating whether DaVita and Fresenius unlawfully suppressed smaller competitors, and an amended class-action complaint (amended September 12, 2025) alleges the two conspired to fix prices, reduce care quality, and allocate markets. A duopoly this concentrated, this dependent on a government rate, with antitrust attention on it, is strong on economics and exposed on politics simultaneously.

Market caps shown for peer-size reference only, with as-of dates; figures move.

6. Industry

Demand for dialysis is driven by the prevalence of kidney failure, which in turn is driven by diabetes and hypertension - the two leading causes of chronic kidney disease. Over 35 million U.S. adults (about 1 in 7) are estimated to have CKD, and roughly 808,000 Americans are living with ESRD, of whom about 69% are on dialysis and 31% have a functioning transplant. Within the dialysis population, in-center hemodialysis dominates (around 433,000 patients) versus home modalities (around 78,000). This is a chronic, demographically-driven demand base: the patient pool grows roughly with the aging population and the diabetes epidemic, and patients stay in the system for years.

The U.S. dialysis market was estimated at roughly $29.5-30 billion in 2024-2025, with forecasts of mid-single-digit growth (roughly 5-6% CAGR) through the early 2030s, driven by rising kidney-disease prevalence, the donor-kidney shortage that keeps patients on dialysis longer, and favorable reimbursement. DaVita sits at the center of the U.S. supply chain as the largest provider of the service itself; the upstream (machines, dialyzers, consumables) is dominated by Fresenius and Baxter, and the downstream payer is the U.S. government.

There is no meaningful "import" dynamic - dialysis is delivered locally, treatment by treatment - but there is a powerful regulatory dynamic that functions similarly. The entire industry's revenue is set by CMS through the ESRD Prospective Payment System (the "bundle"), adjusted annually, with quality incentives layered on top. Policy changes - the phosphate-binder move into the bundle (TDAPA) in 2025, the treatment of Medicare Advantage enrollment, the fate of enhanced ACA premium tax credits, and any shift in how commercially-insured ESRD patients are handled - move the industry's economics more than any operating decision a company makes.

Cyclicality is low in the conventional economic sense (people need dialysis in recessions too), but the industry has its own cycles: clinical/seasonal ones (flu seasons drive mortality spikes that dent census, as happened in early 2025), policy ones (reimbursement rules), and a lingering post-COVID mortality overhang that elevated patient deaths and suppressed census growth across the sector. The structural tailwind is rising prevalence; the structural headwinds are reimbursement pressure, the long-run policy push toward home dialysis and transplant (lower-revenue settings), and antitrust/political scrutiny of the duopoly.

7. Growth Triggers

All items below are drawn from the five concalls, cited by quarter and date. Numbers are management's own statements, included only where needed to make the trigger specific.

• Fresenius clinic closures feeding volume to DaVita. Management raised 2026 volume growth guidance from flat to +25-50 bps, attributing roughly half of the improvement to Fresenius closing clinics and the resulting patient transfers, expected to contribute incrementally through the second half of 2026. (Q1 2026 concall, May 5 2026)

  "Approximately half from underlying performance; half from Fresenius clinic closures."

• Non-recurrence of 2025 volume headwinds. The flu/hurricane/cyber headwinds that cost 75-100 bps of volume in 2025 are not expected to repeat, implying a 50-75 bps structural volume improvement into 2026. (Q3 2025 concall, Oct 29 2025; repeated Q4 2025, Feb 2 2026)

• IKC profitability scaling. After reaching its first profitable year in 2025 (a year early), management guided to an incremental ~$20 million of IKC operating income growth in 2026, with the CKCC program delivering year-over-year improvement across all three key measures. (Q4 2025 concall, Feb 2 2026; reinforced Q1 2026, May 5 2026)

• Mortality-reduction clinical program (the long-cycle volume lever). A three-pronged strategy - better middle-molecule clearance via hemodiafiltration (HDF) and advanced/medium-cutoff dialyzers, broader GLP-1 adoption, and predictive IT - that management says could reduce mortality "by as much as 20% or more," with full effect not expected until roughly 2029 given the implementation lag. Lower mortality directly raises census and treatments. (Q4 2025 concall, Feb 2 2026; flagged Q2 2025, Aug 5 2025 and Q3 2025, Oct 29 2025)

  "The clinical and operational processes behind middle molecule clearance will take approximately three years to see result." - CEO (Q3 2025, Oct 29 2025)

• International expansion, half organic and half M&A. Continued top- and bottom-line growth internationally with margin improvement from overhead leverage; Brazil integration and additional Latin America acquisitions cited. (Q4 2025 concall, Feb 2 2026; Q2 2025, Aug 5 2025)

• Elara Caring home-health integration. The ~$200 million minority investment (alongside Ares) into a home-health provider with kidney-specific protocols, aimed at cutting hospitalizations and missed treatments. (Q4 2025 concall, Feb 2 2026)

• Technology/AI as an operating-income lever. Proprietary EMR plus AI deployment (e.g., ScheduleHub for real-time scheduling), which management positions as supporting a long-run 3-7% operating-income growth algorithm. (Q1 2026 concall, May 5 2026)

• Phosphate-binder (TDAPA) income. The 2025 move of binders into the bundle added roughly $50 million of operating-income contribution, with iron-based binder mix running favorable, though adherence remains a swing factor. (Q1 2025 concall, May 12 2025; Q2 2025, Aug 5 2025)

8. Key Risks

Reimbursement and payer-mix erosion (high-probability, moderate-to-severe drag). The whole profit pool sits in the ~10-11% of treatments paid by commercial insurance. Anything that shrinks that slice - patients aging into Medicare, shifting into Medicare Advantage, or losing exchange coverage - hits profit disproportionately. Management has specifically flagged the expiration of enhanced ACA premium tax credits as a roughly $40 million headwind in 2026, part of an estimated $120 million three-year hit ($40M / $70M / $10M) if the credits lapse, plus a drift toward lower-cost bronze plans that pressures revenue per treatment (Q3 2025, Oct 29 2025; Q1 2026, May 5 2026). The base Medicare rate itself is set annually by CMS and is a permanent overhang.

"Premium Tax Credits: $120 million three-year headwind if enhanced credits expire." - paraphrasing CFO Joel Ackerman's 2026 swing-factor framing (Q3 2025, Oct 29 2025).

Antitrust and regulatory action (lower-probability, potentially severe). The FTC is investigating whether DaVita and Fresenius unlawfully hindered smaller competitors, and an amended class action (Sept 12, 2025) alleges price-fixing, quality reduction, and market allocation. A duopoly with ~37% share each, dependent on a government rate, is a standing political target. An adverse outcome could mean fines, forced divestitures, or constraints on the very local-market density that is the moat.

Patient mortality and census stagnation (high-probability, ongoing drag). This is the most important operating risk and management's most candid one. ESRD patients die at high rates; a bad flu season or a lingering post-COVID mortality overhang directly shrinks the patient base. In 2025 the combination of a severe flu season, Hurricane Helene, and the cyber incident knocked 75-100 bps off volume. Mortality is, in management's words, "a hard variable to know in real time" (Q1 2026, May 5 2026). The entire mortality-reduction program is essentially a multi-year bet to convert this risk into a growth lever, but it doesn't pay off until ~2029.

Cybersecurity (demonstrated, recurring). On April 12, 2025, DaVita suffered a ransomware attack that disrupted operations, forced parts of the network offline, and cost an estimated $40-50 million of revenue impact in Q2 through delayed claims and prior-authorization problems, plus ~$13 million of discrete remediation costs (Q1 2025, May 12 2025; Q2 2025, Aug 5 2025). Dialysis care continued, but the event showed how a clinical-IT-dependent operation can be materially disrupted, and the missed-treatment elevation lingered longer than expected.

Leverage and capital-structure rigidity (moderate, structural). DaVita runs at roughly 3.2-3.4x consolidated EBITDA, near the upper end of its 3.0-3.5x target. The aggressive buyback program is debt-funded in part, and the credit facilities restrict dividends. High leverage limits flexibility if reimbursement or volume deteriorates, and refinancing exposes the company to interest-rate moves (management repriced Term Loan B in July 2025).

Concentration in Berkshire's stake (technical overhang). Berkshire Hathaway owns roughly 45% of DaVita and has been a persistent seller, with DaVita repurchasing shares from Berkshire under an agreement designed to keep Berkshire at or below 45%. This creates a continuous, known supply of stock and makes DaVita's buyback partly a mechanism to absorb its largest holder's selling rather than purely opportunistic capital return.

9. Walk the Talk

Concalls referenced: Q1 2025 (May 12 2025), Q2 2025 (Aug 5 2025), Q3 2025 (Oct 29 2025), Q4 2025 (Feb 2 2026), Q1 2026 (May 5 2026).

The story across these five calls is of a management team that held its full-year financial commitments together through a genuinely rough operating year, was consistently honest about volume disappointment, and was conservative-to-accurate on the items it could control - while being appropriately humble about the one thing it can't (mortality).

Start at Q1 2025. Two things had just gone wrong: a severe flu season had elevated mortality and a ransomware attack had hit on April 12. Management's response was to reaffirm full-year adjusted operating income and EPS guidance, explicitly framing the math as headwinds (a ~50 bps volume decline, cyber costs) offset by tailwinds (Q1 outperformance, higher phosphate-binder income).

"Reiterating its full-year adjusted operating income and earnings per share guidance, despite challenges associated with a difficult flu season... and headwinds related to the recent cyber incident." (Q1 2025, May 12 2025)

At Q2 2025 the volume picture worsened - full-year volume guidance was cut from down ~50 bps to down 75-100 bps, and the cyber incident turned out to have hit revenue per treatment by $40-50 million in the quarter. Yet management again held the full-year OI and EPS ranges. This is the first credibility test, and they passed it the honest way: they admitted the volume miss and the cyber drag plainly rather than burying it, and offset it with better cost control (patient-care cost guidance actually improved) rather than financial engineering. They were candid that phosphate-binder adherence "is not what we expected."

By Q3 2025 the team narrowed the full-year ranges around an unchanged midpoint - the move of a management that is now confident it will land the year - and delivered the key forward message: the 75-100 bps of 2025 volume headwinds (flu, hurricane, cyber) were one-off and would not recur, setting up 50-75 bps of structural volume improvement in 2026. They also pre-disclosed the 2026 swing factors (premium tax credits, MA enrollment, IKC timing) rather than letting them surprise the market later.

Q4/FY 2025 is where the talk met the walk. They delivered adjusted EPS of $3.40 against $3.24 guidance and full-year adjusted OI of about $2.094 billion - i.e., they hit the financial commitments they had defended all year despite the volume shortfall. More notably, IKC reached its first profitable year a full year ahead of the timeline they had set (Q1 2025 had targeted "breakeven by 2027"; they hit profitability in 2025). That is a kept promise, delivered early.

"First profitable fiscal year" for IKC in 2025, "ahead of the originally projected 2026 timeline." (Q4 2025, Feb 2 2026)

Q1 2026 then raised 2026 guidance (OI up ~$40M at midpoint, EPS range lifted) and raised volume guidance from flat to +25-50 bps - validating the Q3 2025 thesis that 2025's headwinds were transient and that Fresenius closures plus normalization would restore growth. The one consistent area of restraint: mortality. Across all five calls management refused to over-claim on mortality trends, repeatedly calling it hard to read in real time and pushing the payoff of the clinical program out to ~2029 - the opposite of overpromising.

The pattern that emerges is a management team that protects its financial guidance and tends to deliver on it, is transparent about operational misses (volume, binder adherence, cyber), beats on the items within its control (cost, IKC timing, capital return), and is deliberately conservative on the long-cycle clinical bets. The fair verdict: this is a "does what they say" management, with a mild bias toward under-promising on the controllable financials and refusing to promise on the uncontrollable clinical ones.

10. Shareholder Friendliness Index

Dividends. DaVita has never paid a cash dividend since its 1994 IPO, and management has stated it has no plans to, with the senior secured credit facilities placing limits on its ability to do so. DPS for each of the last three years was therefore $0.00 - not a cut, but a long-standing structural choice to return capital entirely through buybacks.

Buybacks and dilution. DaVita is an aggressive, programmatic repurchaser, and the share count has been on a multi-year decline (weighted-average shares fell from roughly 96 million in 2022 toward the mid-80s millions by 2024, and lower since). In FY2025 the company repurchased roughly 13 million shares for approximately $1.8 billion (about 10 million / $1.5 billion through the Q3 call, then 2.7 million in Q4, with another 1.7 million bought post-quarter). Through the recent window, Q1 2026 alone saw 3 million shares repurchased plus another 2 million post-quarter. A defining feature: a portion of these repurchases are bought directly from Berkshire Hathaway under a publicly filed agreement designed to keep Berkshire's stake at or below 45% - so the buyback is simultaneously genuine per-share-count reduction and a mechanism to absorb the largest holder's ongoing selling. Leverage has been run at the high end (3.2-3.4x EBITDA) to fund this. (Sources: FY2025 / Q4 2025 8-K and concall, Feb 2 2026; Q1 2026 concall, May 5 2026; prior-year repurchase disclosures in 2024 10-Q/10-K filings.)

Verdict: Returns Capital. DaVita aggressively retires shares and has shrunk its count materially over three years, paying no dividend purely by design rather than by weakness - though investors should note a meaningful share of the buyback is structurally tied to absorbing Berkshire's selling.

11. Insider Activities

Source note. No MoatMap insider block was injected for this report. The venue is the U.S. (NYSE), so the primary source is SEC Form 4 via EDGAR, cross-checked against OpenInsider and StockTitan aggregations. OpenInsider was unreachable during this research (connection refused on two attempts); the figures below come from SEC Form 4 filings as surfaced via StockTitan and corroborating news/aggregator reporting. Insider transaction data for this venue IS publicly accessible; only the OpenInsider mirror was down.

The last 12 months are dominated by one story: Berkshire Hathaway, DaVita's ~45% holder, has been a steady net seller, and DaVita has been buying those shares back under its publicly filed repurchase agreement to hold Berkshire at or below 45%. Company executives have also been net sellers, primarily in routine option/tax-related patterns. There were no material open-market purchases by executives or directors.

Buys - read the signal. There were no meaningful open-market purchases by DaVita insiders in the trailing 12 months. CEO Rodriguez's November 2025 "acquisition" of 7,309 shares was an equity-compensation event (with shares surrendered to cover exercise cost and tax), not a conviction open-market buy, and should not be read as a bullish purchase signal. Over an 18-month look-back, Berkshire made 7 transactions, all net selling ~6 million shares.

Sells - work out the why. The Berkshire selling is the cleanest to explain: it is the contractual/structural unwind under the repurchase agreement that caps Berkshire at 45%, not a verdict on the business - DaVita is mechanically buying the same shares back. The executive sells (Ackerman) are modest in the context of a CFO's equity compensation and are most consistent with routine diversification and option/tax management; specific 10b5-1 plan footnotes were not surfaced in the available filings, so for the executive sells the precise reason is not separately disclosed.

Net assessment. Insiders are net sellers, but the selling is overwhelmingly concentrated in one holder (Berkshire) selling for structural rather than fundamental reasons, with the company absorbing the supply. There is no cluster buying and no executive open-market purchase to flag as bullish. Stripping out the mechanical Berkshire dynamic, insider activity is best read as neutral - the absence of any open-market buying is unremarkable for a company that returns capital via buybacks, but it also means there is no insider conviction-buy signal to point to.

12. Scenarios

Bull case. The 2025 troubles prove to be exactly the one-off that management said they were. Flu-season and post-COVID mortality normalize, and the patient census starts growing again; Fresenius's clinic closures funnel a steady stream of displaced patients into DaVita's centers through 2026, pushing treatment volume back toward the company's long-stated 2% growth ambition. IKC, now profitable a year early, scales into a real second profit engine as more value-based contracts mature and DaVita keeps posting the best shared-savings results in the CMS program. The mortality-reduction program - HDF, advanced dialyzers, GLP-1 adoption - begins to bend the death rate down by the back half of the decade, which in dialysis is the same thing as compounding revenue, because every patient kept alive is years of additional treatments. International keeps adding centers, and the Elara home-health tie-up cuts hospitalizations enough to lift both census and IKC economics. The buyback keeps shrinking the share count against a roughly flat-to-growing profit pool, the FTC and antitrust matters resolve without structural remedies, and DaVita ends up a slowly-growing, cash-gushing, ever-fewer-shares compounder.

Base case. Management does roughly what it has guided. Treatment volume grows modestly (the +25-50 bps raised in early 2026), revenue per treatment rises 1-2% on normal rate increases, and the commercial-mix and premium-tax-credit headwinds shave a bit off but don't break the model. IKC contributes its incremental ~$20 million and grows steadily but unspectacularly; international grows half-organically, half by M&A. The mortality program stays a multi-year story with no near-term payoff. The company keeps running leverage near the top of its range and keeps buying back stock - much of it from Berkshire - so per-share metrics improve faster than the underlying business. The FTC and antitrust overhang lingers as a discount on the stock without forcing a structural change. It is the quiet, durable, government-rate-dependent annuity it has always been: low growth, high cash conversion, steadily fewer shares.

Bear case. The volume "normalization" doesn't come - mortality stays structurally elevated, admits stay soft, and census flatlines or shrinks, removing the one organic growth lever. Simultaneously the profit-rich commercial slice erodes: enhanced ACA premium tax credits expire, patients drift to bronze plans and Medicare Advantage, and revenue per treatment growth stalls just as patient-care costs (labor, drugs) keep climbing - squeezing the thin spread the whole company depends on. The antitrust pressure turns real: an adverse FTC outcome or class-action liability forces divestitures or pricing constraints that attack the local-market density that is the moat. High leverage, run up to fund buybacks, becomes a liability rather than a lever if EBITDA falls, limiting flexibility into refinancings. And the largest shareholder keeps selling. In this world DaVita is a leveraged, no-growth, government-rate-capped business with a regulatory target on its back - the same concentration that made it powerful becomes the thing that makes it fragile.

A note on completeness

• Five concalls: all located and used (Q1 2025 through Q1 2026); most recent is 34 days old.
• Section 13 (Further Reading): omitted. SemiAnalysis, Stratechery, and MBI Deep Dives are tech/semiconductor/equity-tech focused and have no qualifying coverage of DaVita; per the empty-case rule the section is dropped entirely. (A separate Substack, "The 10th Man Deep Dives," has covered DaVita, but it is not one of the three named sources and so is excluded.)
• Insider data: OpenInsider was unreachable; figures are sourced from SEC Form 4 filings via StockTitan and corroborating reporting. Executive-sell reasons (Ackerman) were not separately disclosed in the available filings and are labeled as such rather than guessed.
• Some segment operating-income figures in the charts are management-stated; the "implied core" U.S. dialysis OI is derived by subtracting disclosed International ($114M) and IKC ($22M) from full-year adjusted OI (~$2.094B) and is approximate.

Sources: Q1 2026 transcript (Insider Monkey), Q4 2025 transcript (Insider Monkey), Q3 2025 transcript (Motley Fool), Q2 2025 transcript (Insider Monkey), Q1 2025 transcript (Insider Monkey), DaVita 2025 Annual Report (IR), DaVita FY2025 10-K (SEC), DaVita Q1 2026 8-K (SEC), Berkshire Form 4 / DVA insider activity (StockTitan), Fresenius Medical Care market cap (CompaniesMarketCap), U.S. dialysis market size (GMInsights), Dialysis antitrust litigation (Saveri Law Firm), DaVita vs Fresenius (Morningstar).